Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05460676 · ClinicalTrials.gov registry record · NA
Reducing Tobacco Smoking: a Transcranial Direct Current Stimulation (TDCS) Telehealth Study
A NA study of Smoking Cessation, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT05460676: Recruiting NA study of Smoking Cessation, sponsored by Wake Forest University Health Sciences.
NCT05460676 is a NA study of Smoking Cessation that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 46 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05460676, a NA study of Smoking Cessation, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to evaluate the feasibility of using Dorsolateral Prefrontal Cortex (DLPFC) Transcranial Direct Current Stimulation (tDCS) as a tool to decreasing distress and cigarette smoking. 46 participants currently smoking cigarettes, and seeking to decrease cigarette use will be recruited.
Primary Outcome
The FTQ is a questionnaire is a 10 question survey which will be used to determine the ease and comfort of device use. Each question will be rated on a scale of 1 - 10, with 1 indicating the greatest difficulty or discomfort, and 10 indicating the greatest ease or tolerability. Questions for which the population average is greater than or equal to 5 will be deemed well tolerated.
Conditions Studied
Interventions
- DEVICE Transcranial Direct Current Stimulation (tDCS)
- OTHER Mindfulness
- OTHER Sham - Transcranial Direct Current Stimulation (tDCS)
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-08-15 |
| Est. Completion | 2026-04 |
| Phase | NA |
What NCT05460676 shows while recruiting
NCT05460676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 3 interventions - of which Transcranial Direct Current Stimulation (tDCS) is the first listed.
NCT05460676 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05460676 about?
NCT05460676 is a clinical study titled "Reducing Tobacco Smoking: a Transcranial Direct Current Stimulation (TDCS) Telehealth Study". The study aims to evaluate the feasibility of using Dorsolateral Prefrontal Cortex (DLPFC) Transcranial Direct Current Stimulation (tDCS) as a tool to decreasing distress and cigarette smoking. 46 participants currently smoking cigarettes, and seeking to decrease cigarette use will be recruited.
What is the current status of trial NCT05460676?
This trial is currently recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2023-08-15. Estimated completion is 2026-04.
What conditions does trial NCT05460676 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT05460676?
The interventions under investigation include: Transcranial Direct Current Stimulation (tDCS) (DEVICE), Mindfulness (OTHER), Sham - Transcranial Direct Current Stimulation (tDCS) (OTHER).
Who is sponsoring clinical trial NCT05460676?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05460676 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05460676's enrollment target sits among peer trials
46 154th of 188 higher than 35 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
RECRUITING · NA
-
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
RECRUITING · NA
-
ACT Lung Health Intervention: Phase Two
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
RECRUITING · NA
-
Urban and Reservation Implementation of All Nations Breath of Life
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI